Iniciar sesión Regístrese gratis

Novo Nordisk A/S Ingresos

¿Qué es el Ingresos de Novo Nordisk A/S?

El Ingresos de Novo Nordisk A/S es kr167.195B

¿Cuál es la definición de Ingresos?



Los ingresos son las ganancias que una empresa tiene de sus actividades comerciales normales, generalmente de la venta de bienes y servicios a los clientes.

Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.

In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.

Ingresos de compañías en Sector Health Care en OTC en comparadas con Novo Nordisk A/S

¿Qué hace Novo Nordisk A/S?

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Empresas con ingresos similar a Novo Nordisk A/S